All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES previous systemic treatment (%) previous systemic treatment NO (%) smoker (current or former) smoker (never) stage I stage II stage IIIa
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
lung cancer : non small cell (NSCLC), ... vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results FLAURA, 2018 0.63 [0.45; 0.88]
0.63 [0.45 ; 0.88 ] FLAURA, 2018 1 0% 556 NA not evaluable progression or deaths (PFS)detailed results FLAURA, 2018 0.46 [0.37; 0.57]
0.46 [0.37 ; 0.57 ] FLAURA, 2018 1 0% 556 NA not evaluable DCRdetailed results FLAURA, 2018 2.92 [1.28; 6.68]
2.92 [1.28 ; 6.68 ] FLAURA, 2018 1 0% 556 NA not evaluable objective responses (ORR)detailed results FLAURA, 2018 1.27 [0.85; 1.90]
1.27 [0.85 ; 1.90 ] FLAURA, 2018 1 0% 556 NA not evaluable AE (any grade)detailed results FLAURA, 2018 1.01 [0.32; 3.16]
1.01 [0.32 ; 3.16 ] FLAURA, 2018 1 0% 556 NA not evaluable AE (grade 3-4)detailed results FLAURA, 2018 0.67 [0.47; 0.95]
0.67 [0.47 ; 0.95 ] FLAURA, 2018 1 0% 556 NA not evaluable AE leading to death (grade 5)detailed results FLAURA, 2018 0.59 [0.21; 1.64]
0.59 [0.21 ; 1.64 ] FLAURA, 2018 1 0% 556 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results FLAURA, 2018 0.71 [0.45; 1.13]
0.71 [0.45 ; 1.13 ] FLAURA, 2018 1 0% 556 NA not evaluable SAE (any grade)detailed results FLAURA, 2018 0.81 [0.55; 1.20]
0.81 [0.55 ; 1.20 ] FLAURA, 2018 1 0% 556 NA not evaluable TRAE (any grade)detailed results FLAURA, 2018 0.42 [0.29; 0.60]
0.42 [0.29 ; 0.60 ] FLAURA, 2018 1 0% 556 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 05:20 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 431